悦康药业YKYY013注射液临床试验获批

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries have received approval from the National Medical Products Administration to conduct Phase I clinical trials for YKYY013 injection, aimed at treating chronic hepatitis B virus infection [1] Group 1: Company Developments - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have obtained the clinical trial approval [1] - YKYY013 injection is a chemically synthesized double-stranded siRNA drug that utilizes N-acetylgalactosamine ligands [1] Group 2: Product Details - YKYY013 works through RNA interference to effectively silence the messenger RNA of the HBV genome, thereby inhibiting the production of hepatitis B pathogen proteins and suppressing HBV replication [1] - The drug aims to create conditions for host immune reconstitution, ultimately achieving functional cure for hepatitis B [1]